tetano
Editor, Senior Moderator
Eur J Immunol
. 2024 Aug 2:e2451145.
doi: 10.1002/eji.202451145. Online ahead of print. Immune signature of patients with cardiovascular disease predicts increased risk for a severe course of COVID-19
Manina Günter[SUP] #[/SUP][SUP] 1 2 [/SUP], Karin Anne Lydia Mueller[SUP] #[/SUP][SUP] 3 [/SUP], Mathew J Salazar[SUP] 2 [/SUP], Sarah Gekeler[SUP] 3 [/SUP], Carolin Prang[SUP] 3 [/SUP], Tobias Harm[SUP] 3 [/SUP], Meinrad Paul Gawaz[SUP] 3 [/SUP], Stella E Autenrieth[SUP] 1 2 [/SUP]
Affiliations
Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection can lead to life-threatening clinical manifestations. Patients with cardiovascular disease (CVD) are at higher risk for severe courses of COVID-19. So far, however, there are hardly any strategies for predicting the course of SARS-CoV-2 infection in CVD patients at hospital admission. Thus, we investigated whether this prediction is achievable by prospectively analysing the blood immunophenotype of 94 nonvaccinated participants, including uninfected and acutely SARS-CoV-2-infected CVD patients and healthy donors, using a 36-colour spectral flow cytometry panel. Unsupervised data analysis revealed little differences between healthy donors and CVD patients, whereas the distribution of the cell populations changed dramatically in SARS-CoV-2-infected CVD patients. The latter had more mature NK cells, activated monocyte subsets, central memory CD4[SUP]+[/SUP] T cells, and plasmablasts but fewer dendritic cells, CD16[SUP]+[/SUP] monocytes, innate lymphoid cells, and CD8[SUP]+[/SUP] T-cell subsets. Moreover, we identified an immune signature characterised by CD161[SUP]+[/SUP] T cells, intermediate effector CD8[SUP]+[/SUP] T cells, and natural killer T (NKT) cells that is predictive for CVD patients with a severe course of COVID-19. Thus, intensified immunophenotype analyses can help identify patients at risk of severe COVID-19 at hospital admission, improving clinical outcomes through specific treatment.
Keywords: Cardiovascular disease; Immune signature; Immuno‐response; SARS‐CoV‐2 infection; Spectral flow cytometry.
. 2024 Aug 2:e2451145.
doi: 10.1002/eji.202451145. Online ahead of print. Immune signature of patients with cardiovascular disease predicts increased risk for a severe course of COVID-19
Manina Günter[SUP] #[/SUP][SUP] 1 2 [/SUP], Karin Anne Lydia Mueller[SUP] #[/SUP][SUP] 3 [/SUP], Mathew J Salazar[SUP] 2 [/SUP], Sarah Gekeler[SUP] 3 [/SUP], Carolin Prang[SUP] 3 [/SUP], Tobias Harm[SUP] 3 [/SUP], Meinrad Paul Gawaz[SUP] 3 [/SUP], Stella E Autenrieth[SUP] 1 2 [/SUP]
Affiliations
- PMID: 39094122
- DOI: 10.1002/eji.202451145
Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection can lead to life-threatening clinical manifestations. Patients with cardiovascular disease (CVD) are at higher risk for severe courses of COVID-19. So far, however, there are hardly any strategies for predicting the course of SARS-CoV-2 infection in CVD patients at hospital admission. Thus, we investigated whether this prediction is achievable by prospectively analysing the blood immunophenotype of 94 nonvaccinated participants, including uninfected and acutely SARS-CoV-2-infected CVD patients and healthy donors, using a 36-colour spectral flow cytometry panel. Unsupervised data analysis revealed little differences between healthy donors and CVD patients, whereas the distribution of the cell populations changed dramatically in SARS-CoV-2-infected CVD patients. The latter had more mature NK cells, activated monocyte subsets, central memory CD4[SUP]+[/SUP] T cells, and plasmablasts but fewer dendritic cells, CD16[SUP]+[/SUP] monocytes, innate lymphoid cells, and CD8[SUP]+[/SUP] T-cell subsets. Moreover, we identified an immune signature characterised by CD161[SUP]+[/SUP] T cells, intermediate effector CD8[SUP]+[/SUP] T cells, and natural killer T (NKT) cells that is predictive for CVD patients with a severe course of COVID-19. Thus, intensified immunophenotype analyses can help identify patients at risk of severe COVID-19 at hospital admission, improving clinical outcomes through specific treatment.
Keywords: Cardiovascular disease; Immune signature; Immuno‐response; SARS‐CoV‐2 infection; Spectral flow cytometry.